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Abstract
Several mechanisms have been proposed to account for the marked increase in severity of human infections with avian
compared to human influenza strains, including increased cytokine expression, poor immune response, and differences in
target cell receptor affinity. Here, the potential effect of target cell tropism on disease severity is studied using a
mathematical model for in-host influenza viral infection in a cell population consisting of two different cell types. The two
cell types differ only in their susceptibility to infection and rate of virus production. We show the existence of a parameter
regime which is characterized by high viral loads sustained long after the onset of infection. This finding suggests that
differences in cell tropism between influenza strains could be sufficient to cause significant differences in viral titer profiles,
similar to those observed in infections with certain strains of influenza A virus. The two target cell mathematical model
offers good agreement with experimental data from severe influenza infections, as does the usual, single target cell model
albeit with biologically unrealistic parameters. Both models predict that while neuraminidase inhibitors and adamantanes
are only effective when administered early to treat an uncomplicated seasonal infection, they can be effective against more
severe influenza infections even when administered late.
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Introduction
The potential spread of a severe pandemic influenza is a
worldwide cause for concern. In recent years, attention has focused
on the avian-derived influenza A (H5N1) virus strain, which has the
potential to evolve into a pandemic influenza strain [1]. The swine-
origin influenza A (H1N1) strain which is responsible for the recent
influenza pandemic has been a cause for concern given the strain’s
ability to cause severe illness and the added stress it puts on the
health care system [2–6]. The reasons for the increased severity
observed with some influenza strains are poorly understood and
possible explanations include an excessive cytokine response[7–11],
a poor immune response due to the strain’s novelty [12,13], and
differences in target cell receptor affinity (cell tropism) between
human-adapted, seasonal strains and animal-origin pandemic
strains [14–17]. Recent work has focused on the binding affinity
of different strains of influenza virus for specific cell receptors within
the respiratory tract [18–21] and it is believed that this difference in
affinitybetween human and avian strainsmay inpart be responsible
for the difference in severity between the two strains, though the
reasons for this are currently not well understood.
Two specific cell types are believed to play important roles in
influenza virus infection: ciliated epithelial cells, and nonciliated,
mucus-producing cells. In epithelial cell cultures, nonciliated,
mucus producing cells predominantly express sialic acid a-2,6
galactose terminated saccharides (SAa2,6 Gal) on their surface,
while ciliated cells express sialic acid a-2,3 galactose terminated
saccharides (SAa2,3 Gal) receptors, as well as SAa2,6 Gal
receptors, on their surface [20,22,23]. In vitro experiments have
shown that human-adapted influenza A viruses (H1N1, H3N2)
seem to preferentially bind to SAa2,6 Gal receptors, while avian-
adapted influenza A (H5N1) viruses appear to preferentially bind
to SAa2,3 Gal cell receptors [16]. Due to concerns over the effect
of cell tropism on infection dynamics, most influenza infection
assays are now conducted in Madin-Darby canine kidney
(MDCK) cells which have been transfected to express more
SAa2,6 Gal receptors (called SIATI cells), rather than in regular
MDCKs which predominantly express SAa2,3 Gal receptors [24].
A similar trend has developed for in vivo influenza infection assays
which are now preferably performed in ferrets rather than mice
because the former has lung cells which predominantly express
(human lung-like) SAa2,6 Gal receptors, while the latter mostly
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adoption of ferret models for in vivo assays has been slower than
the adoption of SIAT1 for in vitro assays simply because of the
large cost associated with ferret models. A better understanding of
the infection parameter differences between the mouse and ferret
models could ease the translation of results obtained in mice into
predictions for the course and outcome of infection in ferrets and
humans.
Recently, efforts have been made to model in-host influenza
infection dynamics with a target cell limited model, using
experimental data to validate the results [28–30], but the models
have been limited to a single target cell population. Population
heterogeneity has been accounted for in epidemiological models
[31–34], where individuals become infected through primary
contact with an infected individual, and heterogeneity is
introduced by varying the contact rates between subpopulations.
Due to the absence of an intermediate infection agent (i.e., virions)
in these models, their results are of limited applicability to in-host
infections, where the infection progresses from infected cells to
healthy cells via the production and dispersal of infectious virions.
Target cell heterogeneity has also been considered for within-host
models of HIV [35,36], hepatitis B [37,38] and hepatitis C [39]
and has provided an explanation for multiple phases of infection
[35,39] or different courses of disease progression [36–38].
However, these models are fairly complex, containing multiple
compartments [36,39] or assuming that target cell populations
differ in most or all parameters [35,37,38], making analysis and
interpretation difficult.
In this paper, we propose a mathematical model consisting of
two distinct cell populations which differ only in their susceptibility
to infection by a given viral strain and their rate of virus
production. This choice is motivated by the assumption that
differences in the cells’ surface receptors will most directly affect
the rate at which virus can bind cells to successfully infect them, as
well as the rate at which newly produced virions will be able to
break free from these cells after binding to their receptors upon
budding. This simple model allows us to study the possible effects
of cell tropism on the in-host progression and severity of influenza
infections. By constraining one cell population to the specific
parameter values defined in [28] for in-host human infection with
influenza A (H1N1), we explore the dynamics of the model in the
parameter space of the secondary cell population.
Unfortunately, to date, no publication has attempted to isolate a
specific cell population’s infection characteristics (e.g., viral
production rate, cell infection rates) so it is not possible to use
external data to set the value of the parameters relating to cell
tropism in our model. Therefore, the work presented herein is an
investigation of the effect cell tropism could have on infection
dynamics and treatment strategies, rather than the effect it will
have. We also do not attempt to differentiate between all possible
causes for change in disease severity among different influenza
strains. To our knowledge, there is not enough data available
anywhere, and no data of the right nature (e.g., time course of IFN
levels, Abs levels) to permit such a study.
The aim of this paper is two-fold: (1) to theoretically explore the
parameter space of an infection model consisting in two target cell
populations to understand what role, if any, cell tropism could play
in modulating an influenza infection’s dynamics; and (2) to
consider what implications such an effect would have on treatment
with antivirals. We find that the parameter space of the two target
cell model contains a region of increased disease severity
characterized by a larger viral titer peak and a long-lasting
infection with high, sustained viral titer. We show that the long-
lasting, sustained viral titer seen with more severe infections offers
a longer window for effective treatment with neuraminidase
inhibitors (NAIs) and adamantanes (or M2 blockers).
Methods
Mathematical model
The proposed two target cell model, which consists of two cell
populations both susceptible to influenza virus infection, is an
extension of the differential equation model consisting of a single
susceptible cell population and delayed viral production proposed
in [28], and fitted therein to match the dynamics of a primary
influenza A/HK/123/77 (H1N1) infection in human volunteers.
The two target cell model consists of a population of default
(subscript d) and secondary (subscript s) cells, namely
Target cells :
dTd
dt
~{bTdV
dTs
dt
~{rbbTsV
Eclipse cells :
dEd
dt
~bTdV{kEd
dEs
dt
~rbbTsV{kEs
Infected cells :
dId
dt
~kEd{dId
dIs
dt
~kEs{dIs
Virus :
dV
dt
~pIdzrppIs{cV:
ð1Þ
Infection proceeds as target cells T are infected by virus V at a rate b (or
rbb). The newly infected cells E first enter a latent infection stage, called
the eclipse phase, and turn into productively infected cells I at a rate k.
Productively infected cells produce virus at a rate p (or rpp) which is
cleared at a rate c by the immune system or through loss of
infectivity. The remaining virions go on to infect new target cells,
and the infection progresses.
Differences between the two cell populations are controlled by
three key parameters: rb, rp, and rT. These parameters represent
the fold difference in susceptibility to infection, rb, and viral
production rate, rp, of the secondary cell type compared to that of
the default cell type, and the fraction of cells of the secondary type
in the initial target cell population, rT. For example, setting
(rT,rb,rp)~(0:2,10{3,102) corresponds to a cell population where
20% of cells are of the secondary type and are 1,000-fold less
susceptible to infection compared to cells of the default type, but
once infected these secondary cells will produce 100-fold more
virus than cells of the default type.
While rb and rp are scaling factors for parameters b and p in the
secondary cells, respectively, rT does not appear explicitly in the
model as it is set through the initial conditions for target cells such
that
Initial target cells : Td,0~(1{rT)T0 Ts,0~rTT0 ,
where 0ƒrTƒ1.
The total number of initial target cells is set to T0~4|108 cells,
which is in line with anatomical estimates for the human upper
respiratory tract [28], and infection is initiated by a virus inoculum
V0. Default parameter values and initial conditions for (1) are
listed in Table 1. These parameter values were obtained by
repeating the individual fits to viral titers from six different
volunteers infected with influenza A/Hong Kong/123/77 (H1N1)
presented in [28]. We obtained different best-fit parameters which
resulted in better SSRs than those presented in [28] which is why
the geometric averaged best-fit parameters listed in Table 1 differ
from those reported in [28] (parameters of the individual fits are
available upon request). Numerical solutions of model (1) were
obtained using the lsode function in Octave 3.0.1 [40], which uses
ð1Þ
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method) if the equations are stiff; otherwise, Adam’s (predictor-
corrector) method is used [41].
Fits of the model to experimental data
To assess the validity and relevance of the two target cell model,
we compared its performance to that of the single target cell model
in capturing the dynamics of influenza infection of mice and
humans. For fitting purposes, we define the default and secondary
cell types as cells expressing either the SAa2,6 Gal or SAa2,3 Gal
receptors as described below.
In an effort to reduce the number of free parameters, we fix the
number of total target cells based on measurements of the surface
area of the human upper respiratory tract, 4|108 [28], or of the
mouse lung, 7|109 [42]. Note that the value used for the initial
number of target cells will affect the values obtained for the best-fit
viral production rates, but will not affect the ratio of virus
produced by one cell population to the other. For the mouse
model, we fix the proportion of cells predominantly expressing
SAa2,6 Gal receptors on their surface, r2,6, at 10%. This is an
approximate value based solely on qualitative reports indicating
that mice lung cells predominantly express SAa2,3 Gal receptors
[25–27]. For the human model, we fix the proportion of cells
predominantly expressing SAa2,6 Gal receptors on their surface,
r2,6, at 70%. This is based on studies of human lung physiology
indicating that the epithelium of the upper airway (up to the fifth
generation) comprises 50–85% nonciliated cells [43], and reports
indicating that nonciliated cells predominantly express SAa2,6 Gal
receptors on their surface [20,22,23].
Setting an exact value for the fraction of cells predominantly
expressing SAa2,6 Gal receptors on their surface, r2,6, is not
essential since a change in r2,6 can be corrected by appropriate re-
scaling of p2,6 and p2,3. That is, if r2,6?r
0
2,6 then we have
Target cells : T
0
2,6~
r
0
2,6
r2,6
T2,6 T
0
2,3~
(1{r
0
2,6)
(1{r2,6)
T2,3
Viral production rate : p
0
2,6~
r2,6
r
0
2,6
p2,6 p
0
2,3~
(1{r2,6)
(1{r
0
2,6)
p2,3:
ð2Þ
All other parameters were determined by fitting log10 of the viral titer
predicted by the model to that of the experimental data. The fits
were performed using either the Octave 3.0.1 [40] leasqr function,
which is an implementation of the Levenberg-Marquardt
nonlinear regression method [44], or the nelder_mead_min
function, which uses the Nelder-Mead method for finding the
minimum of a function. The fits presented here are the best fits
found using either one of these methods. For comparison, we also
fit the data using the single target cell eclipse model [28].
To quantify the quality of each fit, we computed the sum of
squared residuals (SSR) between the experimental viral titer and
the models’ results. In order to compare models with different
numbers of parameters, we also computed small-sample size
(second order) Akaike’s ‘‘an information criterion’’ (AICC). The
model with the lowest AICC is considered to be best supported by
the experimental data available.
Results
Mapping the parameter space
Since differences in cell receptor specificity between influenza A
strains of human and avian origin, and changes in viral production
for different cell types have not been quantified [16,45,46], we
consider a wide range of parameter values for the secondary cell
population. The susceptibility to infection of target cells of the
secondary type, rb, and their rate of virus production once
infected, rp, are independently varied from 1,000-fold less (10{3)
to 1,000-fold more (103) than that of the default cell type.
Figure 1 illustrates how the time post-infection at which viral
titer peaks depends on the fold difference in susceptibility to
infection (rb) and viral production rate (rp) of the secondary cell
type compared to that of the default cell type. Here we present
only the case where default and secondary target cells are present
in equal numbers (rT~0:5). Varying the fraction of target cells of
the secondary type results in similar behaviour, except in the case
of a nearly homogeneous cell population composed mainly of cells
of the secondary type (rTw0:918).
When rb~rp~100~1, the two target cell model reduces to the
single target cell model and the viral titer curve reaches a peak
value around 3 days post-infection (dpi), as with the single target
cell model [28]. Not surprisingly, increasing the secondary cells’
susceptibility to infection (rb) or their rate of virus production (rp)
relative to that of the default cell type causes the infection to peak
earlier. This is because with a large rb, cells of the secondary type
are infected more easily and therefore consumed more rapidly by
the infection leading to a shorter-lasting infection. Analogously,
with a large rp, secondary cells release larger amounts of virus once
infected, which in turn leads to a more rapid consumption of all
cell types by the infection. This translates to a shorter-lasting
infection as one moves upwards or rightwards on the graph in
Table 1. Default initial conditions and parameter values of model (1).
Symbol Parameter Value
T0 number of initially available target cells 4|108 cells
E0, I0 number of initially infected cells 0
V0 initial viral inoculum 7.6|10{2 [V]
a
1=k length of eclipse phase 4.2 h
1=d lifespan of productively infected cells 2.9 h
1=c virus clearance rate 2.9 h
b infection rate of cells by virus 1.0|10{5 [V]
21?d
21
p virus production rate 0.20 [V]?d
21
R0 basic reproductive number 12
aViral titer measured in units of ½V ~TCID50=mL of nasal wash.
doi:10.1371/journal.pone.0013811.t001
ð2Þ
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corner of the graph.
In general, over the parameter space explored, the viral titer
peaks between 1 dpi and 4 dpi, with the exception of an
unexpected pocket in the parameter space at the bottom-right of
our graph in the region where cells of the secondary type produce
more virus than cells of the default type (rpw1), but are harder to
infect (rbv1). In the vicinity of this pocket, the time of viral peak
varies rapidly from 2 dpi to more than 8 dpi, becoming
increasingly sensitive to the secondary cells’ susceptibility to
infection and their viral production rate. Within this parameter
region, secondary cells are not easily infected, due to their low
susceptibility to infection (small rb), and as such these cells are
consumed very slowly by the infection. On the other hand, their
high rate of virus production (large rp) means that once infected,
even in very small numbers, these cells produce large quantities of
virus. As a result, the viral titer is sustained at high levels long after
the onset of infection, and peaks substantially later than in other
regions of the parameter space.
This is well illustrated in the three examples presented in
Figure 1(a)–(c) where the kinetics of the infection are shown for
three different viral production rates of the secondary cell
population for the case where these cells are 500-fold harder to
infect than cells of the default type. When secondary cells produce
only 10-fold more virus than cells of the default type, the infection
is mostly limited to the default cell population as the amount of
virus produced is not sufficient for the infection to spread to the
secondary cell population. Increasing the production rate to 100-
fold more than cells of the default type results in a sufficient
amount of virus being produced to sustain a slow growing infection
within the secondary cell population, leading to long-lasting, high-
levels of viral titer. Finally, increasing the viral production rate to
1,000-fold more than the default cell type allows the infection to
successfully consume both cell populations rapidly.
It is important to note that while the secondary cells must be
harder to infect than the default cells, the secondary cells do not
require a higher viral production rate to achieve this sustained
viral titer. The same kinetics can be achieved with secondary cells
Figure 1. Time of viral titer peak for different properties of the secondary cell type. The effect of varying the secondary cells’ susceptibility
to infection (rb) and their rate of virus production (rp) relative to that of the default cell type is illustrated (top) for a population of cells with an equal
abundance of default and secondary cells (rT~0:50). Time of viral titer peak is given in days post-infection (see legend to the right of graph). The
three stars indicate the specific parameter values used in the three graphs (bottom) from left to right (a to c). The graphs depict the viral titer (black),
and the relative abundance of target cells of the default (blue, dashed) and secondary (blue, solid) type over the course of an in-host influenza
infection when the secondary target cells’ susceptibility to infection is 500-fold less, and their virus production rate is (a) 10-, (b) 100-, and (c) 1,000-
fold higher than that for cells of the default type. All other parameter values are given in Table 1.
doi:10.1371/journal.pone.0013811.g001
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cells if the ratio of default to secondary cells is adjusted according
to equations (2). The specific conditions for parameters that lead to
sustained viral titer are discussed further below.
Conditions for infection
Figure 1 suggests that the two target cell model leads to high,
sustained, viral titers over a certain region of the parameter space.
In order to better understand the relationship that needs to exist
between the secondary cell population’s susceptibility to infection
and viral production rate to give rise to a severe, long-lasting
infection, it is useful to consider a linear stability analysis of the
two target cell model. For all parameter values, the equations have
a line of fixed points, corresponding to a stable, uninfected
cell population persisting in the absence of infection, namely
(T ,E ,I ,V )~(Teq,0,0,0), where Teq~Teq,dzTeq,s. Within
each the default and secondary cell types, this equilibrium value
is less than or equal to the initial cell population, i.e.,
Teq,dƒ(1{rT)T0 and Teq,sƒrTT0. Therefore, the stability of a
fixed point is guaranteed by the condition RszRdv1, where
Rd~
bp(1{rT)T0
dc
Rs~
(rbb)(rpp)(rTT0)
dc
:
Thus, when RszRdv1, an initial quantity of virus does not lead
to a substantial infection of the cell population, and growth of the
virus is suppressed. For a single target cell population, i.e., rT~0
or rT~1, the stability conditions are Rdv1 or Rsv1,
respectively.
The three quantities, Rs, Rd and their sum, are analogous to the
basic reproductive number R0, a frequently used quantity in
epidemiology and in-host infection dynamics, which is defined as
the average number of second-generation infections produced by a
single infected cell within a homogeneous population of completely
susceptible cells [47,48]. Although this description of Rd and
Rs may be valid in the case of a homogeneous cell population,
the interpretation for a heterogeneous population is less
straightforward.
For the parameter values presented in Table 1, the quantity Rd
is always greater than one when rTv0:918, resulting in growth of
the viral titer. This results from the choice of default parameter
values, which were taken from an infection where R0w1. When
rTw0:918, regions arise within the parameter space where
RszRdv1; that is, the initial viral titer fails to lead to an
infection. We also see a region where the individual quantities Rd
and Rs are both less than one, but the sum of these quantities is
greater than one. This implies that the infection grows slowly, and
although not explicitly accounted for in our model, the host
immune response would likely intervene before the viral titer
reached symptomatic levels. These cases are illustrated in Figure 2.
In order to narrow our focus to biologically relevant regions of
the parameter space, we will restrict our analysis to the case where
rTv0:918. The quantity Rs~1 will be seen to form a boundary in
the parameter space which establishes a region leading to high
viral loads which are sustained for long periods of time.
Implications for disease severity
Beyond simply mapping the infection kinetics through the
parameter space, it is important to understand the implication of a
given viral titer curve on the severity of infection for a patient. To
this end, we introduce three approximate measures of viral
infection severity: time of viral load peak, approximate duration of
symptomatic infection, and total amount of virus. Each measure
has its advantages and limitations, but together they provide a
Figure 2. Time of viral load peak when the cell population is mostly composed of secondary cells. Different graphs represent different
proportion of secondary target cells, rT, for values ranging from 0:91–0:94. Each graph explores the effect of varying the secondary cells’
susceptibility to infection (rb) and their rate of virus production (rp) relative to that of the default cell type. All other parameters are held fixed at the
values presented in Table 1. The stability condition Rs~1 (black line) is indicated. Grey regions indicate regions where the infection fails to spread to
either cell population (RszRdƒ1). Time of viral titer peak is given in days post-infection (see legend on right side of graphs).
doi:10.1371/journal.pone.0013811.g002
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may be experienced by a patient. Other possible measures of
disease severity which may be more difficult to estimate clinically
are presented in Appendix S1.
In order to focus on the specific parameter region which results
in severe, long-lasting infections characterized by high-level,
sustained viral loads, we restrict our analysis to the region of the
parameter space bounded by rb, the relative susceptibility of
secondary cells to infection, from 10{6 to 100, and rp, the relative
viral production rate by secondary cells, from 100 to 106.
Time of viral titer peak. A useful measure of disease
severity is the time at which the viral load reaches its maximum
value. This is an important measure because, as seen in [28], when
treatment with a neuraminidase inhibitor such as oseltamivir is
applied after viral titer peak, it has little effect on disease severity
and duration. Thus, the time of viral titer peak provides an
estimate of the time window available for effective treatment. In
general, an early viral titer peak means that both external
treatment or host immunity has little opportunity to act to reduce
disease morbidity. The dependence of the time of viral titer peak
on the secondary cells’ infection characteristics are shown in
Figure 3(a).
As the secondary cells’ susceptibility to infection (rb) and their
viral productivity (rp) decrease, the viral titer peaks progressively
later, going from 1 dpi to as late as 16 dpi. In the region where
Rs*1, the late peak of viral titer is due to the slow consumption of
the secondary cells. This late viral titer peak means that even
relatively late treatment with antivirals could have a noticeable,
beneficial effect in reducing disease morbidity and perhaps
avoiding mortality in such infections. We will return to this below
when we simulate treatment of these infections with neuramini-
dase inhibitors and adamantanes.
Symptomatic infection duration. Though our model
predicts that viral titer can peak significantly later for certain
parameter regimes, this does not necessarily imply a sustained,
severe infection. For example, it is important to distinguish
between a small, slow growing infection, and one which grows
rapidly and is maintained over a long period of time, with a late
viral titer peak. While the former would likely be cleared effectively
by an immune response before it has the chance to fully develop,
the latter might already be too severe by the time the immune
response gets underway, resulting in a severe infection rendered
more morbid by the extensive immune response triggered by the
high and long-lasting viral titer. Thus, we establish another
measure of infection severity, which we define as the duration of
the symptomatic infection. The dynamical markers for disease
severity are not well known, but based on patient symptom scores,
the onset of symptoms in a human-derived influenza infection
appears to take place sometime between 1–2 dpi, and to dissipate
around 5–6 dpi [49,50]. On the viral titer curves for human-
derived strain infection, these two time points correspond
approximately to places where the viral titer curve crosses 10
4
TCID50/mL (see Figure 1(a)). Thus, we set this viral titer as the
threshold level corresponding approximately to that required for a
symptomatic infection. Following this convention, we define the
duration of the symptomatic infection to be the length of time for
which the viral titer remains above the symptomatic threshold.
This is shown in Figure 3(b).
We find that the region corresponding to a late peak of the viral
load in Figure 3(a) also corresponds to a viral load sustained above
the symptomatic threshold long after the onset of infection. The
viral titer surpasses the symptomatic threshold at approximately 2
dpi, as we can see in Figure 1(b). We can therefore exclude the
possibility that the late peak of the viral titer results from the slow
and steady growth of the viral titer. Rather, the late peak is the
result of sustained viral titer at high levels. This behaviour can be
explained by considering the infection of the two populations
separately. After the default cell population is completely
consumed by the infection, approximately 3 dpi, an essentially
homogeneous population of secondary cells remains. The quantity
Rs is then analogous to the basic reproductive number for the
secondary cell population. Thus, when Rs is slightly greater than
one, growth of viral titer occurs slowly, and the viral titer is
sustained at the high levels produced during infection of the
default cell population, as illustrated in Figure 1(b). This also has
implications for treatment strategies. While a long lasting
treatment regimen usually makes little sense for treating seasonal
influenza infections, it would be beneficial if not necessary for
controlling a longer-lasting infection characterized by sustained
viral production.
Total virus produced. In assessing infection severity, it is
also helpful to consider the total amount of virus produced over
the course of the infection. Severe influenza viral infections are
characterized by high viral loads [51], which does not necessarily
follow from a delayed peak of the viral titer or a long symptomatic
infection. The total amount of virus produced during the course of
infection was determined using
Vtotal~
ð?
0
(pIdzrppIs)d t:
The results within the parameter space are shown in Figure 3(c).
When Rsv1, the total amount of virus produced is independent of
rb and rp as the viral titer does not grow to sufficient levels to
establish an infection within the secondary cell population. When
Rsw1, there are sufficiently large rates of virus production and
target cell infectivity for the infection to spread within the
secondary cell population. Figure 3(c) illustrates that when Rsw1,
the amount of virus produced is predominantly dependent on the
scaling factor for the rate of virus production, rp. When rp is large,
a significant amount of viral titer is produced and a large number
of cells from both populations are consumed, regardless of the
secondary cells’ susceptibility to infection. However, as rp
decreases, the quantity Rs approaches one, and the presence of
long-lasting infection becomes increasingly sensitive to variations
of either rp or rb.
This feature is particularly interesting when framed within the
context of anti-influenza drug treatment. For infection character-
ized by Rsw1, depending on the value of rp and rb, i.e. where you
are in the parameter space, it is sometimes preferable to treat with
an antiviral targeting the secondary cells’ susceptibility to infection,
rb, such as an adamantane so as to move downwards in the
parameter space to most easily reach Rsv1. In other cases, it is
more beneficial for an equivalent drug efficacy to treat with an
antiviral targeting the secondary cells’ viral production rate, rp,
such as a neuraminidase inhibitor so as to move leftwards in the
parameter space to most easily reach Rsv1.
Note that the plot for total virus produced as a function of rb
and rp is identical in feature to that of another important measure:
the total amount of free virus which is defined as the area under
the curve (AUC) of free virus (V) over time (t). The total amount of
free virus is important as it is related to the epidemiological (host-
to-host) transmission fitness of a particular strain [30].
Fits of the model to experimental data
We have seen that the two target cell model is capable of
producing high, sustained, viral titers. To determine whether these
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PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e13811Figure 3. Measures of disease severity for varying properties of the secondary cell population. The effect of varying the secondary cell’s
susceptibility to infection (rb) and their rate of virus production (rp) compared to that for cells of the default type on different measures of disease
severity: (a) time of viral titer peak, (b) duration of symptomatic infection and (c) total amount of virus produced. We have adjusted the axes to
examine the region of sustained viral titer. Note that the value of the disease severity measures in the top left corner of each graph (rb,rp =1,1)
corresponds to the single target cell model. All other parameters are set as specified in Table 1, with rT~0:5. The stability condition Rs~1 is also
indicated (black line).
doi:10.1371/journal.pone.0013811.g003
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for severe influenza infections in vivo, and to compare our two
target cell model’s performance to that of the single target cell
model, we fitted both models to measurements of influenza
infections in mice [52] and humans [7].
From here on, we will refer to the two target cell populations as
those predominantly expressing SAa2,6 Gal or SAa2,3 Gal surface
receptors rather than as ‘‘default’’ and ‘‘secondary’’ cells.
Accordingly, we replace parameters b, p, rbb, and rpp, with
parameters b2,6 and p2,6, the infection and production rates
associated with cells predominantly expressing SAa2,6 Gal
receptors on their surface, and b2,3 and p2,3, the infection and
production rates associated with cells predominantly expressing
SAa2,3 Gal receptors on their surface, which are easier to
interpret in terms of what they represent biologically.
Influenza infection in mice. In the first data set, BALB/c
mice were infected intranasally with 102 pfu of A/Texas/36/91
(H1N1), A/1918 (H1N1), A/Thailand/SP/83/2004 (H5N1), or
A/Thailand/16/2004 (H5N1) influenza virus. Lungs from 3 mice
were harvested and homogenized at 1, 3, 4, 5, and 7 dpi. Virus
titers were determined by plaque assay in MDCK cells. Although
two of the strains are avian-derived and the other two are human-
derived, all four strains produced infections with high, sustained,
viral titers. This is surprising given that mice lung cells
predominantly express SAa2,3 Gal receptors on their surface
[25–27] and as such one would expect that strains which prefer
SAa2,3 Gal receptors (e.g., H5N1) would replicate more effectively
in mice than those which prefer SAa2,6 Gal receptors (e.g.,
H1N1).
Figure 4 shows our model fits to influenza infections in mice,
with the solid line indicating the best fit for the single target cell
model and the dashed line indicating the best fit for the two target
cell model. Parameters for the best fits are given in Table 2.
Visually, it appears that both models can adequately capture the
dynamics of both human- and avian-strain influenza infections in
mice. While the SSR are always smaller for the two target cell
models because it has two additional free parameters, the AICC
are comparable between the two models suggesting that the two
target cell model is equally well supported by the experimental
data despite its additional parameters.
It is, however, also important to consider whether the parameter
values of the best fits are biologically realistic. The basic
reproductive numbers, R0, obtained with the single target cell
model are rather large (w810) compared to those obtained for
with the two target cell model (R2,6zR2,3*3–23) which are more
in line with values obtained typically (R0*3–75) for infections
with human strains [28,29]. In addition, while the values obtained
for the eclipse delay (1=k) and infected cell lifespan (1=d) are
unrealistically large for the fits of the single target cell model, these
values are typically reasonable for the two target cell model fits.
Figure 4. Model parameter fits to experimental influenza infection in mice. Results of parameter fits of the single target cell (solid line) and
two target cell (dashed line) eclipse model to human-strain (A/Texas/36/1991 and A/1918) and avian-strain (A/Thai/SP/83/2004 and A/Thai/16/2004)
influenza infections in mice. The percentage of cells expressing the SAa2,6 Gal receptor, r2,6, is fixed to 10%, and the best fit parameters are presented
in Table 2. For the single target cell model, the SSRs are (from left to right and top to bottom) 0.45, 2.8|10{4, 7.8|10{3, and 3.3|10{4 while the
AICC are 235, 272, 256, and 271. For the two target cell model, the SSRs are 0.29, 2.1|10{19, 2.3|10{3, and 7.4|10{5 while the AICC are 232,
2240, 256, and 274. Data is taken from [52].
doi:10.1371/journal.pone.0013811.g004
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base values from Table 1 and found that under this constraint, the
single target cell model does poorly (SSR *7|10{422)
compared to the two target cell model (SSR *4|10{1820.3,
results not shown).
Unfortunately, interpretation of the cell tropism of these four
strains from their parameter values for the two target cell model
fits is awkward. All four strains display a preference for cells
expressing SAa2,3 Gal over those expressing SAa2,6 Gal
(R2,3wR2,6), with human strains exhibiting a stronger preference
for cells expressing SAa2,3 Gal than avian strains. This is not
consistent with expectations that the two human-adapted H1N1
strains should prefer cells expressing SAa2,6 Gal while the avian-
derived H5N1 strains should prefer cells expressing SAa2,3 Gal.
This could be a consequence of the overparametrization (8
parameters for 5 data points). The set of best fit parameters
presented here is part of a larger family of best fit parameters sets
which capture this data equally well (see for example the rescaling
of r2,6, p2,6 discussed in the Methods section), and which likely
contains more reasonable cell tropism parameters which would fit
the data equally well. If some of the parameters of the two target
cell model could be resolved through experiments, it would restrict
the set of possible parameter values which could help validate or
invalidate the two target cell model.
Therefore, while the single- and two-target cell models each
provide good fits which are well supported by the data, the two
target cell model does so under more realistic parameter values,
suggesting that it offers a better description of the dynamics.
However, this likely says more about the limitations of the single
target cell model than about the appropriateness of the two target
cell model. Indeed, one can imagine that other extensions of the
single target cell model (e.g., by including an immune response)
would do equally well if not better than the two target cell model.
Influenza infection in humans. The second data set
consists of pharyngeal and nasal swabs collected from 18
patients infected with avian (H5N1) influenza, and 6 patients
infected with human influenza (either H1N1 or H3N2) upon
admission to hospital. This data set shows a clear dynamical
difference between human- and avian-adapted influenza strains,
with avian-strain infections peaking later and lasting longer than
infections with human-adapted influenza strains.
Figure 5 shows several fits of the single- and two-target cell
models to data from natural human- and avian-strain influenza
infections in humans with the resulting parameters given in
Table 3. The solid line uses the single target cell model and the
remaining lines use the two target cell model. While the SSR is
comparable for the fits of the single- and two-target cell models,
the lower AICC for the fit of the single target cell model to the
avian strain infections suggests that it may be better supported
than the two target cell model by the limited data available.
Fits of the single target cell model yielded mostly reasonable
parameter values with the increased severity of avian-derived
strains compared to human strains reflected in the larger R0 value
(5.3 vs 3.2). The parameter fits of the single target cell model
suggest that compared to human-derived strains, the avian strains
infect cells less effectively (smaller b), but once infected, cells
produce more virus (larger p). In addition, the longer infected cell
lifespan (1=d) and smaller viral clearance rate (c) for avian strains
could be the result of a less effective immune response to the novel,
avian-derived strains. However, the data is too limited to lend any
weight to these interpretations.
For fits of the two target cell model, the best fit parameters,
especially those characterizing cell tropism, depend on the value
used as the guess for the initial viral inoculum, V0, when
initializing the fitting programme. When initialized with a high
value for V0 (dotted line in Figure 5), the solver converges to fits
which reduce the two target cell model to a single target cell model
(R2,6v1 or R2,3v1) for both human- and avian-strain infections.
When initialized with a low value for V0 (dashed line in Figure 5),
the solver converges to fits in which both cell populations
participate in the infection for both human- and avian-strain
infections.
Table 2. Model parameter fits for experimental influenza infection in mice.
V0 ([V]) 1=k (h) 1=d (h) 1=c (h)
b2,6=b2,3
(½V 
{1:d{1) p2,6=p2,3 (½V :d{1) R2,6=R2,3 SSR AICC
Single target cell model
LH 5.9|10{3 4.4|105 7.3 1.2 1.1|10{3/2 7.7/2 8.8|105/2 0.45 235
LA 8.2 240 130 0.41 6.9|10{5/2 0.019/2 810/2 2.8|10{4 272
HH 65 33 32 34 9.8|10{5/2 0.0012/2 1600/2 7.8|10{3 256
HA 1.5|105 16 ? 7.1 5.9|10{7/2 0.0027/2 ?/2 3.3|10{4 271
Two target cell model (r2,6~0:1)
LH 4.1|10{3 24 0.74 0.80 2.4|10{8/
8.2|10{4
77/0.0030 1.3/16 0.29 232
LA 1.4 9.2 1.1 1.3 2.7|10{7/
3.3|10{5
2.9/0.0039 1.3/2.0 2.1|10{19 2240
HH 19 4.9 5.0 5.0 5.2|10{8/
2.4|10{5
0.90/0.0033 1.4/22 2.3|10{3 256
HA 4.8|103 2.9 3.5 3.8 4.1|10{8/
9.4|10{5
2.4/2.2|10{4 1.6/3.0 7.4|10{5 274
LH: Low-pathogenic human A/Texas/36/91 (H1N1).
HH: High-pathogenic human A/1918 (H1N1).
LA: Low-pathogenic avian A/Thai/SP/83/2004 (H5N1).
HA: High-pathogenic avian A/Thai/16/2004 (H5N1).
doi:10.1371/journal.pone.0013811.t002
A Model for Mild & Severe Flu
PLoS ONE | www.plosone.org 9 November 2010 | Volume 5 | Issue 11 | e13811Unlike the fits to the mice data, fits to the human data give
reasonable parameter values for both models. The key difference
between the fits of the single and two target cell models is that the
former appears to require larger initial viral inoculum to fit the
infections with avian strains. This is because the sustained viral
titer suggested by the data can only be captured by the single
target cell model when infection proceeds slowly through the only
cell population available, allowing the infection to be sustained. In
turn, the slow infection growth requires that viral titer be high
from the start to match the high levels seen in the data. It is
possible that the single target cell model is correct and that
influenza infections with avian-derived strains are actually initiated
with larger initial inoculum compared to seasonal infections with
human-adapted strains. For example, this could be a consequence
of the former being contracted directly through contact with
infected animals which could result in larger initial inoculum
compared to seasonal infections which are most likely contracted
though airborne particulates.
However, it is possible that the difference in inoculum between
infections with human- vs avian-derived strains is merely a
consequence of the dynamical limitations of the single target cell
model, and that in fact both natural infections are initiated with
similar inoculum. To explore this possibility, we also present the
result of fits of the two target cell model where the initial inoculum
is fixed to an intermediate value (V0~1 cDNA=mL, dash-dot line
in Figure 5) for both infections with human and avian strains. The
resulting best fit is essentially a single target cell model for human-
strain influenza and a two target cell model for the avian-strain
infections.
Regardless of the initial inoculum, fits with the two target cell
model suggest that human strains infect cells expressing the
SAa2,6 Gal receptor on their surface more easily than those
expressing the SAa2,3 Gal receptor (b2,6wb2,3). In contrast, avian
strains infect cells expressing the SAa2,3 Gal receptor more easily
(b2,6vb2,3). This is in line with what we know of these strains’
preferences, with human strains preferring cells expressing SAa2,6
Gal receptors and avian strains preferring those expressing SAa2,3
Gal receptors. More quantitative information such as measure-
ments of the infection rates of each strain in each cell population
would be required to properly calibrate the model and assess the
Table 3. Model parameter fits for influenza infection in humans.
V0([V]) 1=k(h) 1=d(h) 1=c(h) b2,6=b2,3 (½V 
{1:d{1) p2,6=p2,3 (½V :d) R2,6=R2,3 SSR AICC
Single target cell model
H 180 7.3 1.2 1.4 1.2|10{5/2 0.25/2 3.2/2 1.6 ?
A 1300 16 4.5 3.4 2.4|10{7/2 2.0/2 5.3/2 22 29
Two target cell model (r2,6~0:7)
HH 8.4 2.3 2.3 0.94 1.6|10{5/1.8|10{9 0.14/600 2.4/0.5 1.6 285
AH 590 11 1.6 2.2 1.2|10{11/1.4|10{7 3100/31 0.061/3.1 21 44
HL 9.1|10{5 6.2 1.1 9.3 5.2|10{5/1.6|10{4 0.036/0.061 13/69 1.6 285
AL 5.0|10{8 11 1.4 1.1 1.2|10{7/4.5|10{3 34/0.015 3.0/20 21 44
HF (1.0) 3.3 4.4 3.6 3.8|10{5/2.5|10{6 0.22/43 7.3/0.48 1.6 2141
AF (1.0) 1.9 0.78 9.0 9.6|10{8/2.0|10{3 7.6/0.0018 2.5/5.0 22 35
H,A: Fits to the human and avian data sets, respectively.
H,L,F: Indicates whether the initial guess for the viral titer was high, low, or fixed, respectively.
doi:10.1371/journal.pone.0013811.t003
Figure5.Modelparameterfitsofhumanandavianinfluenzainfections in humans. Results ofparameter fits of natural humaninfections with
either a human (left) or avian (right) influenza strain. The data was fit using either the single target cell (solid) or the two target cell model where the fits
were initialized with a guess for the virus inoculum which was either high (dotted), low (dashed), or fixed at 1 cDNA (dash-dot). The percentage of cells
expressing the SAa2,6 Gal receptor, r2,6, is fixed to 70%, and the best fit parameters are presented in Table 3. Data is taken from [7].
doi:10.1371/journal.pone.0013811.g005
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the production rates of virus between cell types and viral strains.
In the end, as indicated by the AICC and SSR, the single target
cell model is statistically the better explanation for both human-
and avian-strain influenza as there is simply not enough data to
support the extra parameters of the two target cell model. Thus,
while the experimental data does not reject the possibility of cell
tropism playing a role in driving the dynamical difference between
infections with human versus avian influenza strains, it cannot
confirm it either.
Drug treatment in the two target cell model
Having extracted parameter values which can capture the
dynamics of infections with human or avian influenza strains in
humans enables us to explore how the predictions of the two
models differ with respect to the efficacy of treatment with
antivirals. Specifically, we compare the effect of treatment with
neuraminidase inhibitors (NAIs), which block the release of viral
particles, and adamantanes, which prevent uncoating of the virus,
on human- and avian-strain influenza infections modelled with
either a single target cell model (solid line of Figure 5) or a two
target cell model (dashed line of Figure 5). The effect of NAIs is
modelled as a reduction in the virus production rates, p2,6 and p2,3,
by multiplying them by (1{e), where 0ƒev1 is the efficacy of
the drug. Adamantanes are modelled in a similar fashion except
that the effect of the drug is to reduce b2,6 and b2,3 when they
appear in the equation for E2,6 or E2,3, a formulation suggested by
Beauchemin et al. [29]. We set e~0:98 [28,30] and examine the
effects of prophylactic treatment, as well as treatment initiated at 2,
3, and 6 dpi.
Figure 6 shows the effect of NAI treatment on viral titers over
the course of human infections with either a human (left column)
or an avian (right column) influenza strain modelled using either
the single target cell model (top row) or the two target cell model
(bottom row). For infections with human influenza strains, the
predictions made by the single target cell model suggest that
antivirals will be more effective than predicted by the two target
cell model. This is because for the particular parameters used here
for the single and two target cell models for infections with human-
derived strains, infection in the two target cell model grows and
peaks more rapidly, making delayed treatment interventions less
effective. For infections with avian influenza strains, the predic-
tions made by the single and two target cell models are similar,
although the two target cell model predicts that treatment will be
slightly more effective than predicted by the single target cell
model. That is because in this case, it is the infection in the single
target cell model which grows and peaks more rapidly, making
delayed treatment less effective. Figure 7 shows the effect of
adamantane treatment on the same human and avian infections.
The results are similar to what is seen for NAIs although
adamantanes do not reduce the duration of the infection as much
as NAIs. The administration of NAIs initially causes a rapid drop
Figure 6. NAI treatment of human infections with either human or avian influenza strains. Viral titer over the course of infections with
either a human or avian influenza strain modelled with either a two target cell model (low V0, dashed line of Figure 5) or a single target cell model
(solid line of Figure 5) in the presence of drug treatment is shown. NAIs are applied either prophylactically (dashed line), at 2 dpi (dotted line), at 3 dpi
(dash-dot line), or at 6 dpi (dash-dot-dot line) with an efficacy of 0.98. Prophylactic treatment lines cannot be seen in the case of the two target cell
model since the initial viral inoculum is below the range of the graph and prophylactic treatment suppresses the infection.
doi:10.1371/journal.pone.0013811.g006
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effect that is not seen when adamantanes are administered.
Ultimately, these four simulations show that what determines
the effectiveness of delayed treatment with antivirals is simply the
growth rate of the infection and the time of viral titer peak.
Infections which proceed slower and peak later provide an
increased window of opportunity in which to administer antiviral
treatment. In contrast, a fast infection which peaks early is not a
good candidate for antiviral treatment because when administered
on or after viral titer peak antivirals have little or no effect on
reducing the severity and duration of the infection. Both the single
and two target cell models predict that in contrast with seasonal
infections which respond best to antiviral treatment when it is
administered within 2 dpi, delayed antiviral treatment of infections
with more severe influenza strains can be effective in reducing the
viral load and shortening the duration of the infection even when
administered late.
Discussion
It has been suggested that differences in disease severity between
human- and avian-derived influenza virus infections may in part
be due to differences in target cell tropism between the two viral
subtypes [16,22]. In order to determine how cell tropism affects
the dynamics of an influenza virus infection, we developed a
mathematical model consisting of two different target cell
populations: a default and a secondary population. The secondary
cell population differs from the default population only in its
susceptibility to infection and rate of virus production. The two
target cell model is a simple extension of the single target cell
model with delayed viral production introduced by Baccam et al.
[28].
We found that within a certain area of the parameter space, the
viral load in the two target cell infection model quickly rises to high
levels and high viral production is maintained over extended
periods of time. The two target cell model displays this behaviour
when the secondary population is such that Rs is slightly greater
than 1. The infection proceeds when the default cell population
falls prey to the infection and is consumed rapidly (*2). This in
turn increases the viral load to levels sufficient to initiate infection
of the more refractory secondary cell population. Once infection is
established within the secondary population, it is consumed slowly
by the virus resulting in a long and severe infection.
In order to determine whether these sustained viral titers are
representative of the dynamics observed for severe influenza
infections in vivo, and to see whether those dynamics can be
captured with reasonable parameter values, we compared our two
target cell model’s performance to that of the single target cell
model by fitting both models to measurements of influenza
infections in mice [52] and humans [7]. Fits to data from infections
in mice with one of four different strains (two human strains and
two avian strains) indicated that the two target cell model was
Figure 7. Adamantane treatment of human infections with either human or avian influenza strains. Viral titer over the course of
infections with either a human or avian influenza strain modelled with either a two target cell model (low V0, dashed line of Figure 5) or a single
target cell model (solid line of Figure 5) in the presence of drug treatment is shown. Adamantanes are applied either prophylactically (dashed line), at
2 dpi (dotted line), at 3 dpi (dash-dot line), or at 6 dpi (dash-dot-dot line) with an efficacy of 0.98. Prophylactic treatment lines cannot be seen in the
case of the two target cell model since the initial viral inoculum is below the range of the graph and prophylactic treatment suppresses the infection.
doi:10.1371/journal.pone.0013811.g007
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compared to the single target cell model. And while fits of the
single target cell model to the experimental data resulted in
reasonable fits, these fits were made possible through unrealistic
parameter values. When parameters were fixed to more
biologically reasonable values, the two target cell model remained
in good agreement with the data, but the single target cell model
performed poorly. This indicates that the single target cell model is
not adequate to capture the dynamics of these infections, and that
the two target cell model is more appropriate. However, other
extensions of the single target cell model with additional parameter
values could likely do as well as the two target cell model. Fits to
data of human infections with either human- or avian-derived
influenza strains indicated that both the single and two target cell
models could fit the data equally well with reasonable parameter
values, and the single target cell model was best supported (smaller
AICC) by the limited amount of data available. Overall, the fits
suggested that while the two target cell model is more appropriate
than the single target cell model to capture a wider range of
infection dynamics within reasonable parameter ranges — which
is not surprising given its two additional parameters —
experimental data was insufficient to reject or confirm the cell
tropism hypothesis offered by the two target cell model.
We also used the models parametrized through the fits of the
human infection data to explore how the single and two target cell
models differed in their predictions of the effectiveness of antiviral
treatment of influenza infections with human or avian strains. The
predictions from both the single and two target cell models were
similar and indicated that while treatment of seasonal influenza
infections (human-derived strains) with antivirals is of limited
effectiveness when treatment is administered more than 2 dpi,
treatment of more severe influenza infections (e.g. avian-derived
strains) can be effective even when administered late.
In order to give rise to high viral titers, sustained over several
days, the cell tropism hypothesis suggests that, for the parameter
values chosen in this paper, the secondary cell population is more
difficult to infect than the default one. It further suggests that once
infected, these secondary cells produce more virus than cells of the
default type. While it is readily acceptable that default and
secondary cells have differing infection rates on the basis that
differences in cell receptor expressions on different cell populations
undoubtedly affect cell-virus binding rates making some cells
harder to infect for certain virus strains, the latter requirement is
less obvious. It is helpful to recall that through the re-scaling of the
parameters (2), it possible to achieve the same kinetics with
secondary cells producing as much or even less virus than cells of
the default type. In the absence of further information regarding
possible differences in viral production rates between the two cell
types, it is still interesting to consider what factors could be
responsible for such differences. It could be that the genotype
which changes the virus’ ability to infect a cell population which
produces more virus also leaves the virus with an impairment in its
ability to be transmitted to another host, say specifically because of
its receptor preference. For example, the SAa2,3 Gal receptors are
predominantly found on the surface of ciliated cells but also in
mucin. So while a virus which adapts to target SAa2,3 Gal
receptors could have access to supposedly higher viral producing
cells (if such cells exist), this would come at the price that many of
these virions would be much less readily transmitted to another
host due to an increase in their rate of mucus binding at the
expense of target cell binding. It is also likely that viral infectivity is
not independent of the rate of production of free virions. In the
two target cell model the virus production rate, p, stands for both
virus production and release. If many virions are produced but are
not readily released, p will effectively be smaller. If a cell is harder
to infect, this is likely due to weaker cell-virus receptor binding
(weak HA activity) making the virus ‘‘less sticky’’ which would
likely results in higher viral release rates even for equivalent viral
production rates, and hence an increase in p.
While it has been established that cell tropism plays a role in
shaping influenza dynamics [53,54], there is insufficient data at
this point to establish whether this role is significant or not when
contrasted against the role of other likely factors such as reduced
immunity or a virus-induced upregulation of cytokines, in shaping
the severity of the infection. If more experimental data, both in
terms of quantity (e.g., more viral titer over a longer time period)
and diversity (e.g., levels of interferon, antibodies, cell viability)
were to become available, one could construct different models
incorporating the most likely factors and it may be possible to
eliminate some of these factors. In order to evaluate the validity of
the predictions made by the two target cell model, it would be
useful to have more viral titer measurements during the early
phase of the infection. Our model produces viral titer with a kink
or bend when the infection in the default cell population reaches a
peak which should be visible in experimental data collected
sufficiently frequently during this early time. In addition, single-
cycle viral yield experiments in the presence of differing ratios of
the two cell types would indicate whether, and by how much, viral
production rates differ between different cell types for different
strains [55].
Regardless of whether or not cell tropism plays a significant role
in shaping infection dynamics, we believe that the two target cell
model is valuable because it can capture dynamics that the simpler
single target cell model cannot with the addition of only two more
parameters: the rate of infection of the secondary cells by the virus,
and the rate of virus production in these cells. In addition, the
nature of these two extra parameters allows them to act as generic
stand-ins for a multitude of other effects including a reduced
immune response. For example, the secondary cell population
could correspond to cells which would not normally get infected
(e.g., slightly deeper in the lung) because the immune response
would clear the infection before it gets to these cells. In this
context, a seasonal influenza infection could be characterized as
having an infection rate for the secondary cells which would be
negligible compared to that for a more severe influenza infection
where infection of these secondary cells would become possible
and would be reflected by a larger secondary cells’ infection rate,
albeit one that is much smaller than that of the default target cell
population. The increased viral production rate could simply result
from the fact that later in the infection, the immune response
begins to contract (e.g., interferon seems to disappear even in the
continued presence of infection, see [42]) and as such production
of virus late in the infection, i.e., when the secondary cells get
infected, would be higher at that time (or in these cells, since at
that time only these cells are left) than at earlier times when the
immune response was still strong. Thus, we see the two target cell
model as a versatile stand-in for a range of phenomena which, in
our opinion, can be captured in a generic way by these two
parameters.
The two target cell model does not explicitly include an immune
response or cell regeneration. This may appear to be a critical
oversight given that some of the infections captured by the two
target cell model can last up to 16 dpi. Since our analysis focuses
solely on viral titers, and not cell numbers, over time, proper
consideration of cell regeneration is relevant only if these
regenerated cells can participate in the infection and are infectible
to the same extent as the original target cell population. This is not
necessarily the case. For example in rodents, the epithelium is
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ciliated cells appearing in 10–14 days, and complete regeneration
in 6 weeks [43]. These regeneration times would likely be longer in
human lungs such that cell regeneration may not have a significant
effect on infection dynamics even when considering long-lasting
infections. Another mathematical model which includes cell
regeneration to capture influenza infections in mice over the
course of 10 days found regeneration times upwards of 67 d
suggesting that either cell regeneration did not play a significant
role in these infections, or that the effect of cell regeneration could
be accounted for implicitly through the other parameters of the
model [42]. While we did not present our results here, we did
study the effect of incorporating cell regeneration into our two
target cell model at a rate of 0.25 d
21 [42] and found that it did
not significantly affect the dynamics of the model over the course
of the main infection (* the first 16 days). However, as is often the
case when models incorporate cell regeneration, the dynamics on
longer time scales was characterized by large, unrealistic,
oscillations. This, in our opinion, supports the hypothesis that
newly regenerated cells do not participate in the infection in a
significant manner or at least have significantly reduced infect-
ibility. The immune response, however, is certainly not negligible
and likely plays an important role, especially in later times.
Unfortunately, while several publications have attempted to
extend the mathematical model for influenza in humans to
include an immune response [56–58], all were theoretical
explorations with insufficient experimental data to support the
extensions and parametrize the response. Models incorporating a
simple immune response have been used to fit experimental data
from animals [42,59,60] and can, under some parameter regimes,
produce long-lasting viral titers. Thus we feel this is an area to be
explored. Unfortunately, in the absence of sufficient experimental
data characterizing the immune response in humans, it is not
possible to incorporate it into our model in a convincing way.
Hopefully, as discussed above, some of the components of the
immune response have been incorporated into our model’s
parameter values in a implicit way.
Finally, given that the two target cell model proposed here
explicitly takes into consideration cell tropism, its biggest
contribution may be its application to translating results obtained
in one host or cell culture system (e.g., mouse, MDCK) into
predictions for the course and outcome of infections in another
host or cell culture system (e.g., human, ferret, differentiated
human epithelium cells). As such, we feel that it will be a very
useful tool as more quantitative data about cell infection rates and
viral production rates of cells for infections with different influenza
strains become available. In addition, since our model is a simple
extension of the classic viral dynamics model used to capture in-
host infection with a variety of other viruses such as HIV [35,61],
and Hepatitis viruses [37,38,62,63], our conclusions also apply to
these other diseases where different cell types can be affected by
the virus.
Supporting Information
Appendix S1 Exploring cell tropism as a possible contributor to
influenza infection severity.
Found at: doi:10.1371/journal.pone.0013811.s001 (0.45 MB
PDF)
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